Details of the 10 patients in the open-label trial PatientSymptomsResponseOutcome 1Acute confusional state and psychosis No signs or symptoms Relapse of.

Slides:

Advertisements

Similar presentations

Lupus in Pregnancy Darren Farley, MD Clinical Assistant Professor

Advertisements

SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Sytemic Lupus Erythematosis The New Understanding: Complexity and Promise Jan L Hillson MD.

Systemic Lupus Erythematosus in children. Objectives Student will be able to define Lupus Student will be able list at least 3 clinical manifestation.

Overview of Multiple Sclerosis  Valerie Robinson, D.O. 

Classification of mental illness Syndrome definition Two major Classification Systems  International classification of Disease ICD-10  Diagnostic and.

Treatment of Vasculitis: immunesuppressives and biologics

Systemic Lupus Erythematosus

Erik Messamore, MD, PhD Psychosis: Origin, Occurrence, Treatment.

Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 23 Drugs for Multiple Sclerosis.

Agne Paner, MD Assistant professor of Medicine RUSH University Medical Center.

Oct. 14 There is no evidence of bowel obstruction or dilatation. 1. Extensive axillary, mediastinal, abdominal, pelvic lymphadenopathy, as above, most.

Medical Management of Ulcerative Colitis Conrad Beckett Bradford Royal Infirmary M62 Course March 2006.

CBT for psychosis PREP Kate Hardy, Clin.Psych.D Post Doctoral Fellow

Assessment Approach Dr. Hunt. Areas of Assessment Basic Medical record Urgent Symptom Disease Symptom-based condition.

This lecture was conducted during the Nephrology Unit Grand Ground by a Sub-intern under Nephrology Division, Department of Medicine in King Saud University.

SEULI BOSE BRILL, MD MEDICINE AM REPORT 2/9/10 Neuropsychiatric Lupus.

Stuttering and Medications City of Chicago NSA Chapter March 26, 2015.

A 17-year-old girl with encephalomyelitis Teaching NeuroImages Neurology Resident and Fellow Section © 2015 American Academy of Neurology.

Psychotherapies in Treatment of Depression Copyright © World Psychiatric Association.

Nervous System Diseases & Disorders Notes. Head Trauma #1 cause of trauma deaths in US Many possible mechanisms of injury: Falls Motor vehicle crashes.

A UTOIMMUNE D ISORDERS. A RTHRITIS O VERVIEW One of the most common, disabling diseases Three types: Osteoarthritis Gout Rheumatoid Arthritis.

Challenging issues about vasculitis

Classification of Psychiatric Disorders

Copyright © 2011 McGraw-Hill Australia Pty Ltd PPTs t/a Abnormal Psychology: Leading Researcher Perspectives 2e by Rieger et al. Edited by Elizabeth Rieger.

A MR spectroscopy study P. Wang, R. Harris, P. Cagnoli, D. Frechtling, D. Bekris, S. Gebarski, J. McCune, and P. Sundgren.

Biomedical treatment By Mr Daniel Hansson. Biomedical treatment What is it? What is it? Supporting studies Supporting studies How can it be used to treat.

Resting Membrane Potential. Resting Membrane Potential & Goldman Equation P = permeability –at rest: P K : P Na : P Cl = 1.0 : 0.04 : 0.45 Net potential.

Magnetic Resonance Imaging In Young Patients With Neuro - Psychiatric SLE : A Case Series Dr. Vivek Gupta Department of Radiodiagnosis Postgraduate Institute.

Cognitive behavioural therapy (CBT) and exercise for neuromuscular conditions Mark Hamilton Research Fellow in Clinical Genetics University of Glasgow.

Systemic lupus erythematous with lupus nephritis Diagnosis & Treatment

Systemic Lupus Erythematosus Angelique Davis Q: Why does seal have scars on his face? A: Discoid Lupus.

Autoimmune Disorders During Pregnancy -Lupus -Antiphospholipid syndrome Rovnat Babazade, MD Obstetrical Anesthesia-2016.

Psychological treatment of Schizophrenia

Algorithm for diagnosis and initial therapy of systemic lupus erythematosus (SLE). For guidelines on management of lupus and lupus nephritis, see BH Hahn.

The long-term impact of psychotherapy in patients with refractory angina Patel PA2, Ali N1, Thapar S1, Sainsbury PA1 1Department of Cardiology, Bradford.

Table 1. Patients Characteristics

Clinical course after Rituximab

“MEDICAL” MARIJUANA. “MEDICAL” MARIJUANA So Dude, whassup? What’s out there? SCIENCEY stuff What does it do for/to you? Politics and policy (and what.

Major Depressive Disorder: Latest Clinical Update

Program Overview. Primary Care Approaches to Cognitive Dysfunction in Major Depressive Disorder.

Autoimmune Encephalitis

افسردگی شناخت، ارزیابی، و پیشگیری در جمعیت دانشجویی

افسردگی شناخت، ارزیابی، و پیشگیری در جمعیت دانشجویی

EULAR Lupus Nephritis Trials Network Study Group 2017

Consultant Psychiatrist and Research Fellow, IoPPN.

Ferrajoli A et al. Proc ASH 2010;Abstract 1395.

EVITA Trial design: Smokers admitted with an acute coronary syndrome were randomized to varenicline 1 mg twice daily (n = 151) vs. placebo (n = 151). Study.

Hiroshi Ureshino, MD, Masaharu Miyahara, MD, PhD

Nat. Rev. Rheumatol. doi: /nrrheum

Antidepressant Discontinuation Syndrome

The Challenges of Bipolar Disorders

Hashimoto’s Encephalitis

ETIOLOGY OF ABNORMAL PSYCHOLOGY

Psychological Support for Kleine-Levin Syndrome

Steroid responsiveness and frequency of relapse in adult-onset minimal change nephrotic syndrome Masaru Nakayama, MD, Ritsuko Katafuchi, MD, Tetsuro.

SOLID-TIMI 52 Trial design: Participants within 30 days of an acute coronary syndrome (ACS) were randomized to darapladib 160 mg daily (n = 6,504) versus.

Medical Approach Physicians began using medical models to review the physical causes of these disorders. Etiology: Cause and development of the disorder.

Figure Overview of patients with demyelinating diseases, presence of clinical symptoms frequently associated with NMDAR encephalitis, and antibody status.

MATRIX: Radial vs. Femoral

The pattern of alteration of HCQ, prednisolone and/or ISS drugs by physicians in a patient with a history of major organ involvement from their SLE (renal.

CONSORT flow diagram for the randomised controlled trial of the iCBT-MDD programme for people with diabetes. iCBT-MDD, internet-based cognitive behaviour.

Result of coronary angiogram among patients with and without diabetes admitted with first-time acute coronary syndrome (a significant stenosis was defined.

Supplemental Fig 1 (A) (B) (B) 59% % alive 52% Years from entry 59%

Serum anti-neuronal antibodies (anti-N) in patients with positive serum anti-GRP78. Serum anti-neuronal antibodies (anti-N) in patients with positive serum.

EULAR Lupus Nephritis Trials Network Study Group

(A) Mean urine protein/creatinine ratio (UPCR) and SEM in participants from the combined Lupus Nephritis Assessment of Rituximab (LUNAR) and A Study to.

Depressed Mood Disorders and Disturbances ≤3.1%

Imaging studies in patients attaining objective response on phase I study. Imaging studies in patients attaining objective response on phase I study. A,

Networks of treatment comparisons for primary outcomes of SLE agents in patients with SLE. The size of the nodes (blue circles) corresponds to the number.

Presentation transcript:

Details of the 10 patients in the open-label trial PatientSymptomsResponseOutcome 1Acute confusional state and psychosis No signs or symptoms Relapse of nephritis at 22 m; rituximab reapplied but failed 2Acute confusional state No signs or symptoms Relapse of autoimmune hemolytic anemia at 18 m; rituximab reapplied and patient improved 3Acute confusional state and seizures No signs or symptoms Relapse of NPSLE at 23 m; IV cyclophosphamide Tanaka Y et al. Arthritis Rheum 2005; 52(9 Suppl):Poster 431. Rituximab for refractory neuropsychiatric SLE [Rheumawire > News; Nov 14, 2005]

Details of the 10 patients in the open-label trial PatientSymptomsResponseOutcome 4Severe headacheReduction of headache Remission maintained for 24 m 5Demyelinating syndrome Reduction of paresthesia Relapse of NPSLE at 7 m; IV cyclophosphamid e 6Mood disorderImprovement of depressive state Remission for 7 m Tanaka Y et al. Arthritis Rheum 2005; 52(9 Suppl):Poster 431. Rituximab for refractory neuropsychiatric SLE [Rheumawire > News; Nov 14, 2005]

Details of the 10 patients in the open-label trial PatientSymptomsResponseOutcome 7Myelopathy, mood disorder, anxiety disorder Reduction of paresthesia, improvement of depressive state Remission for 9 m 8Psychosis, cognitive dysfunction Improvement of psychosis Remission for 6 m 9Acute confusional state, psychosis No signs or symptoms Remission for 6 m 10Acute confusional state, psychosis No signs or symptoms Remission for 24 m Tanaka Y et al. Arthritis Rheum 2005; 52(9 Suppl):Poster 431. Rituximab for refractory neuropsychiatric SLE [Rheumawire > News; Nov 14, 2005]